

DF/HCC

DANA-FARBER / HARVARD CANCER CENTER

## Office for Human Research Studies

### ***Revisions to Letter to Sponsors Concerning DFCI IRB Policy on Re-Consenting Subjects***

OHRS has revised the Letter to Sponsors to provide more detailed information on when the DFCI IRBs require subjects in approved research to be re-consented. Generally, DFCI IRBs only require re-consent if (1) the investigator states in an amendment or other document that subjects will be re-consented; or (2) if a new risk has been identified that impacts the risk/benefit ratio in the approved research. The Letter to Sponsors has more specific information.

[Click to view revised Letter to Sponsors.](#)

Please feel free to contact OHRS if you have any questions.

**Office for Human Research Studies**  
**20 Overland Street**  
**2nd Floor**  
**Boston, MA 02115**  
**Phone: 617-632-3029**  
**Pager: 4-2299**

DF/HCC  
Member  
Institutions

Beth Israel Deaconess Medical Center / Brigham and Women's Hospital / Children's Hospital Boston /  
Dana-Farber Cancer Institute / Harvard Medical School / Harvard School of Public Health /  
Massachusetts General Hospital

NCI  
CCC

A Comprehensive Cancer  
Center Designated by the  
National Cancer Institute